Effect of Previous INR Control during VKA Therapy on Subsequent DOAC Adherence and Persistence, in Patients Switched from VKA to DOAC
Thrombosis and Haemostasis · 2024-08 · 124 (08) · 778-790
DOI: 10.1055/a-2168-9378 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 09.10.2023. Verfasst von Tessa Elling und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: International Normalized Ratio, Vitamin K, Anticoagulants, Drug Monitoring. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Current guideline suggests a switch from vitamin K antagonist (VKA) to direct oral anticoagulant (DOAC) in patients with low time in therapeutic range (TTR < 70%). Poor international normalized ratio (INR) control may be the result of poor compliance, and might therefore be associated with subsequent DOAC intake. Therefore, this study evaluates the effect of previous TTR and other measures of INR control on DOAC nonadherence and nonpersistence, in patients who switched from VKA to DOAC.
Methods
A total of 437 patients who switched from VKA to DOAC between 2012 and 2019 were included using data from Certe Thrombosis Service, IADB.nl pharmacy community database University Groningen, and Statistics Netherlands. DOAC prescriptions were used to determine nonadherence and nonpersistence. INR control (i.e., TTR, time under therapeutic range [TUR], and INR variability) was assessed during the last 180 days of VKA use. Multivariable regression models were applied to determine the association between INR control and DOAC nonpersistence/nonadherence.
Results
On VKA, 67.7% of the patients had a TTR below 70%. DOAC nonpersistence was 39.8% (95% confidence interval [CI]: 33.4–45.5%) during a median follow-up of 34.4 months (interquartile range: 19.1–49.2). Approximately 80% of persistent patients were DOAC-adherent. Low TTR was not associated with DOAC nonpersistence (hazard ratio: 1.14, 95% CI: 0.69–1.87) and DOAC nonadherence (odds ratio: 1.38, 95% CI: 0.67–2.84), nor were TUR and INR variability.
Conclusion
Previous INR control during VKA therapy is not associated with subsequent DOAC nonadherence and nonpersistence. This study suggests that INR control on VKA cannot, and therefore should not, be used for predicting DOAC adherence or persistence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
- Groningen Research Institute of Pharmacy, Unit of Pharmacotherapy, Epidemiology and Economy, University of Groningen, Groningen, The Netherlands.
- Certe Thrombosis Service, Groningen, The Netherlands.
- Department of Epidemiology, University of Groningen, University Medical Centre, Groningen, The Netherlands.
ORCID-Profile: Tessa Elling
Zitieren
APA
Elling, T., Hak, E., Bos, J. H., Tichelaar, V. Y. I. G., Veeger, N. J. G. M., & Meijer, K. (2024). Effect of Previous INR Control during VKA Therapy on Subsequent DOAC Adherence and Persistence, in Patients Switched from VKA to DOAC. Thrombosis and Haemostasis, 124(08), 778-790. https://doi.org/10.1055/a-2168-9378
Vancouver
Elling T, Hak E, Bos JH, Tichelaar VYIG, Veeger NJGM, Meijer K. Effect of Previous INR Control during VKA Therapy on Subsequent DOAC Adherence and Persistence, in Patients Switched from VKA to DOAC. Thrombosis and Haemostasis. 2024;124(08):778-790. doi:10.1055/a-2168-9378
BibTeX
@article{Elling2024,
author = {Elling, Tessa and Hak, Eelko and Bos, Jens H and Tichelaar, Vladimir Y I G and Veeger, Nic J G M and Meijer, Karina},
title = {Effect of Previous INR Control during VKA Therapy on Subsequent DOAC Adherence and Persistence, in Patients Switched from VKA to DOAC},
journal = {Thrombosis and Haemostasis},
year = {2024},
volume = {124},
number = {08},
pages = {778--790},
doi = {10.1055/a-2168-9378}
}
EUVIMED